Find a Trial

Trial Results


243 protocol(s) meet the specified criteria
0810010067/J591OPEN TO ACCRUAL
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) with Ketoconazole in Patients with High Risk Castrate Biochemically Relapsed Prostate Cancer after Local Therapy
1381-0009OPEN TO ACCRUAL
14-006OPEN TO ACCRUAL
CLINICAL VALIDATION OF A URINE-BASED ASSAY WITH GENOMIC AND EPIGENOMIC MARKERS FOR PREDICTING RECURRENCE DURING SURVEILLANCE FOR NON-MUSCLE INVASIVE BLADDER CANCER
14-13546OPEN TO ACCRUAL
Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients with Suspected Lower Respiratory Tract Infection
1650-CL-0201OPEN TO ACCRUAL
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects with Incurable Platinum Refractory Germ Cell Tumors
1808097542OPEN TO ACCRUAL
Racial Disparities in Curative Therapies for Hepatocellular Carcinoma
1811529718OPEN TO ACCRUAL
Introducing Palliative Care (PC) within the Treatment of End Stage Liver Disease (ESLD): A Cluster Randomized Controlled Trial
20170543OPEN TO ACCRUAL
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With a Specific KRAS Mutation.
2018-0877OPEN TO ACCRUAL
Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2)
207497OPEN TO ACCRUAL
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants with Relapsed / Refractory Multiple Myeloma DREAMM-6
516-003OPEN TO ACCRUAL
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
A011401OPEN TO ACCRUAL
RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF WEIGHT LOSS IN ADJUVANT TREATMENT OF OVERWEIGHT AND OBESE WOMEN WITH EARLY BREAST CANCER
A011502OPEN TO ACCRUAL
A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL
A021502OPEN TO ACCRUAL
RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER AND DEFICIENT DNA MISMATCH REPAIR
A041701OPEN TO ACCRUAL
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A151216OPEN TO ACCRUAL
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ADVL1514OPEN TO ACCRUAL
A PHASE 1 STUDY OF ABI-009 (NAB-RAPAMYCIN) IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS AS A SINGLE AGENT AND IN COMBINATION WITH TEMOZOLOMIDE AND IRINOTECAN
ARN-MIRATI-516-005OPEN TO ACCRUAL
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
ARO-021OPEN TO ACCRUAL
Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
AURORAOPEN TO ACCRUAL
AURORA US: Retrospective Tissue Collection
BBI-DSP0509-101OPEN TO ACCRUAL
A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, in Adult Patients with Advanced Solid Tumors
BLCCOPEN TO ACCRUAL
Blue Light Cystoscopy with Cysview (BLC with Cysview) Registry
BTCRC-AML17-113OPEN TO ACCRUAL
Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: Big Ten Cancer Research Consortium BTCRC-AML17-113
BTCRC-AML18-342OPEN TO ACCRUAL
Phase I trial of azacitidine plus nivolumab following reduced-intensity allogeneic PBSC transplantation for patients with AML and high-risk myelodysplasia
BTCRC-HEM17-092OPEN TO ACCRUAL
Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib Big Ten Cancer Research Consortium BTCRC-HEM17-092
BTCRC-LUN16-081OPEN TO ACCRUAL
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
BTCRC-LUN17-127OPEN TO ACCRUAL
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer
BTCRC-LUN17-139OPEN TO ACCRUAL
C-145-03OPEN TO ACCRUAL
A phase 2, multicenter study to evaluate the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
C16-168OPEN TO ACCRUAL
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects
C16-174OPEN TO ACCRUAL
DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
C16011CLOSED TO ACCRUAL
A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
CABOZANTINIBOPEN TO ACCRUAL
NF-105: A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects with Neurofibromatosis Type 1 age 16-65 years
CC06-C-0213OPEN TO ACCRUAL
Tissue Procurement Protocol for the Development Therapeutics Clinic, National, Cancer Institution (NCI)
CTO-17-101OPEN TO ACCRUAL
Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
CTO-20180101OPEN TO ACCRUAL
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer
CTO-20180144OPEN TO ACCRUAL
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors
CTO-20190135OPEN TO ACCRUAL
A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
CTO-68284528MMY2003OPEN TO ACCRUAL
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma
CTO-BTCRC-BRE18-337OPEN TO ACCRUAL
Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337
CTO-BTCRC-LUN18-153OPEN TO ACCRUAL
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
CTO-BTCRC-LUN19-396OPEN TO ACCRUAL
A phase II study of adjuvant treatment with cisplatin-based chemotherapy plus concomitant atezolizumab in patients with stage I (tumors > 4cm), IIA, IIB, and select IIIA [T3N1, T4N0-1] resected non-small cell lung cancer (NSCLC) and the clearance of circulating tumor DNA (ctDNA)
CTO-D3618C00002OPEN TO ACCRUAL
A Phase I, Open-label, Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination with Novel Agents in Patients with Metastatic Castration Resistant Prostate Cancer
CTO-EA2187OPEN TO ACCRUAL
A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
CTO-EAZ171OPEN TO ACCRUAL
Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women
CTO-GOG-3024/GCT1015-05OPEN TO ACCRUAL
CTO-GOG-3031-RUBYOPEN TO ACCRUAL
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN- PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY)
CTO-IUSCC-0701OPEN TO ACCRUAL
Immunological Profile Changes In Patients with Advanced Non-Small Cell Lung Cancer Undergoing Treatment
CTO-IUSCC-0715OPEN TO ACCRUAL
Pilot study of a mobile health strategy to improve medication adherence in breast cancer survivors receiving aromatase inhibitors
CTO-IUSCC-0718OPEN TO ACCRUAL
A quality improvement project to increase knowledge and referrals to the IU breast cancer prevention program
CTO-IUSCC-0722OPEN TO ACCRUAL
Circulating tumor DNA as a predictive biomarker to individualize therapy in patients with stage III non-small cell lung cancer
CTO-IUSCC-0723OPEN TO ACCRUAL
Evaluating the incidence and outcomes of patients with stage III non-small cell lung cancer (NSCLC) whose tumors harbor STK11 and/or Keap1 mutations treated with chemoradiation (CRT) followed by consolidation immunotherapy
CTO-IUSCC-0726OPEN TO ACCRUAL
Significance of STK11/LKB1 or Keap1 mutations in Stage III Non-Small Cell Lung Cancer
CTO-IUSCC-0729OPEN TO ACCRUAL
Non-coding mutations in Multiple Myeloma
CTO-LUN18-335OPEN TO ACCRUAL
CTO-M19-345OPEN TO ACCRUAL
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors
CTO-MK-3475-866OPEN TO ACCRUAL
A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
CTO-MK-3475-905OPEN TO ACCRUAL
A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscleinvasive Bladder Cancer (KEYNOTE-905)
CTO-NCICOVIDOPEN TO ACCRUAL
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
CTO-ODO-TE-S101OPEN TO ACCRUAL
An Open-Label Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients with Advanced Solid Tumors
CTO-PRE0113/REO028OPEN TO ACCRUAL
A study to assess overall response rate by inducing an inflammatory phenotype in Metastatic Breast Cancer with the Oncolytic Reovirus Prelareorep in Combination with anti-PD-L1 Avelumab and Paclitaxel (BRACELET - 1)
CTO-PRE0405OPEN TO ACCRUAL
Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age
CTO-QBGJ398-302OPEN TO ACCRUAL
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)
CTO-S1801OPEN TO ACCRUAL
A PHASE II RANDOMIZED STUDY OF ADJUVANT VERSUS NEOADJUVANT MK-3475 (PEMBROLIZUMAB) FOR CLINICALLY DETECTABLE STAGE III-IV HIGH RISK MELANOMA
CTO-S1803OPEN TO ACCRUAL
PHASE III STUDY OF DARATUMUMAB/rHuPH20 (NSC- 810307) + LENALIDOMIDE OR LENALIDOMIDE AS POST-AUTOLOGOUS STEM CELL TRANSPLANT MAINTENANCE THERAPY IN PATIENTS WITH MULTIPLE MYELOMA (MM) USING MINIMAL RESIDUAL DISEASE TO DIRECT THERAPY DURATION (DRAMMATIC STUDY)
CTO-SNDX-6352-0503OPEN TO ACCRUAL
A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX- 6352 in Subjects with Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Prior Therapy, Including Ibrutinib
CTO-STRO-001-BCM1OPEN TO ACCRUAL
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, An Anti CD74 Antibody Drug Conjugate, in Patients with Advanced B-Cell Malignancies
CTO-VE800-001OPEN TO ACCRUAL
Phase 1 Study of VE800 and Nivolumab in Patients with Selected Types of Advanced or Metastatic Cancer
DB102-02OPEN TO ACCRUAL
DERM-IIR-DFSPOPEN TO ACCRUAL
Dermatofibrosarcoma Protrubrans (DFSP) treated with Mohs Micrographic Surgery: Risk Factors and Treatment Outcomes.
E4412OPEN TO ACCRUAL
A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma.
E4512OPEN TO ACCRUAL
A Phase III Double Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
EA1131OPEN TO ACCRUAL
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
EA2165OPEN TO ACCRUAL
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
EA4151/BMTCTN1601OPEN TO ACCRUAL
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
EA6134OPEN TO ACCRUAL
A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumuab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFFV600 Mutant Melanoma
EA6174OPEN TO ACCRUAL
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
EA8143OPEN TO ACCRUAL
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
EA8153OPEN TO ACCRUAL
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
ESO17-325OPEN TO ACCRUAL
A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients with Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) high Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
GI-CPDPC-MATHER-DETECTOPEN TO ACCRUAL
CPDPC 16-04: Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT)
GI15-225OPEN TO ACCRUAL
A Pilot Study of Pembrolizumab in Combination with Y90 Radioembolization in Subjects with Poor Prognosis Hepatocellular Carcinoma with Preserved Liver Function
GU17-289OPEN TO ACCRUAL
A Phase II Randomized, Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma
GU17-295OPEN TO ACCRUAL
A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma
IUCRO-0031OPEN TO ACCRUAL
Molecular and Pathological Correlates of Treatment Outcome in Patients with Thymoma and Thymic Carcinoma
IUCRO-0042OPEN TO ACCRUAL
Blood Drawing for Study of Peripheral Blood T-Lymphocytes and Other Parameters in patients with Metastatic Melanoma and Renal Cell Cancer with Spontaneous Regression
IUCRO-0049OPEN TO ACCRUAL
Immunologic, Genetic, Molecular, and Pathological Correlates with Clinical and Treatment Outcome in Patients with Renal Cell Carcinoma
IUCRO-0209OPEN TO ACCRUAL
The Susan G. Komen Tissue Bank at the IU Simon Cancer Center: A Collection and Storage of Biological Specimens Intended for use in the Elucidation of Breast Carcinogenesis
IUCRO-0216OPEN TO ACCRUAL
Indiana University Simon Cancer Center Hematologic Malignancies Tissue Bank
IUCRO-0280OPEN TO ACCRUAL
IU Simon Cancer Center Tissue Bank
IUCRO-0309OPEN TO ACCRUAL
IU Pancreatic Lesion Tissue/Fluid Bank
IUCRO-0370OPEN TO ACCRUAL
Pathobiology of Paget's Disease
IUCRO-0450OPEN TO ACCRUAL
Concordance of sensitivity and resistance testing between Cisplatin and Ifosfamide in Soft Tissue Sarcomas: A Retrospective Review
IUCRO-0476OPEN TO ACCRUAL
A Study of the Effect of Sirolimus Levels on Incidence of Hepatic Sinusoidal Obstructive Syndrome
IUCRO-0495OPEN TO ACCRUAL
Creation of a Pancreatic Cancer Outcome Database with Blood Storage
IUCRO-0514OPEN TO ACCRUAL
Collection Of Specimens And Clinical Data To Create A Biorepository For Metastatic Breast Cancer
IUSCC-0523OPEN TO ACCRUAL
Perioperative pelvic floor muscle training may improve recovery of continence in men with localized prostate cancer undergoing robot-assisted radical prostatectomy.
IUSCC-0556OPEN TO ACCRUAL
Pilot study of the effect of weight loss on breast tissue and blood biomarkers in women at increased risk for breast cancer
IUSCC-0574OPEN TO ACCRUAL
A PHASE I/II STUDY TO EVALUATE THE SAFETY, PHARMACODYNAMICS AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH ENTINOSTAT AND BEVACIZUMAB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
IUSCC-0579OPEN TO ACCRUAL
Salvage High Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors: Indiana University Experience 1990-2015
IUSCC-0584OPEN TO ACCRUAL
COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY FOR THE GENITOURINARY ONCOLOGY PROGRAM
IUSCC-0586OPEN TO ACCRUAL
Biomarkers of endothelial dysfunction in pediatric patients receiving high intensity chemotherapy/irradiation
IUSCC-0588OPEN TO ACCRUAL
Glycosylation of exosomes in prostate and urothelial carcinoma
IUSCC-0601OPEN TO ACCRUAL
Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children
IUSCC-0605OPEN TO ACCRUAL
Evaluating dose de-escalation in whole brain radiation therapy with simultaneous integrated boost for patients with brain metastases
IUSCC-0608OPEN TO ACCRUAL
T-Cell Leukemia/Lymphoma Biorepository
IUSCC-0611OPEN TO ACCRUAL
Retrospective Analysis of Patients with Metastatic Germ Cell Tumor at Indiana University
IUSCC-0615OPEN TO ACCRUAL
Pilot Ex-Vivo Investigation of an Experimental Beta Probe for Assessment and Guidance of Prostate Cancer Resection
IUSCC-0621OPEN TO ACCRUAL
Pilot Feasibility Study of Changes in Gene Regulation and DNA Methylation Following Music Therapy
IUSCC-0627OPEN TO ACCRUAL
A Phase II Study Analyzing Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients with 1 4 Brain Metastases
IUSCC-0630OPEN TO ACCRUAL
COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY AND REGISTRY FOR INFLAMMATORY BREAST CANCER
IUSCC-0639OPEN TO ACCRUAL
Comparative analysis of biodynamic imaging utility in predicting response to gemcitabine chemotherapy for human and canine mycosis fungoides
IUSCC-0640OPEN TO ACCRUAL
Collection of Specimens and Clinical Data to Create an Exceptional Toxicity Biorepository
IUSCC-0645OPEN TO ACCRUAL
Description of Cardiotoxicity Associated with Sunitinib in Renal Cell Carcinoma
IUSCC-0658OPEN TO ACCRUAL
The Role of 68Ga-PSMA-11 PET in MRI Fusion Biopsy and Surgery Guidance in Prostate Cancer
IUSCC-0659OPEN TO ACCRUAL
Assessing tobacco use and cessation support among patients with non-tobacco related cancers
IUSCC-0661OPEN TO ACCRUAL
Collection of Specimens and Clinical Data to Create A Biorepository for the Multiple Myeloma Program: The Indiana Multiple Myeloma Biobank
IUSCC-0669OPEN TO ACCRUAL
Pilot study evaluating different methods of circulating tumor DNA quantification in radiation oncology patients
IUSCC-0670OPEN TO ACCRUAL
Beyond the Lung Cancer Diagnosis: Leveraging the Oncology Clinic Setting as a Potential Teachable Moment for Actively Smoking Family Members
IUSCC-0678OPEN TO ACCRUAL
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
IUSCC-0688OPEN TO ACCRUAL
A Retrospective Tissue Analysis of NQO1 Status in Patients with Germ Cell Tumors
IUSCC-0690OPEN TO ACCRUAL
Assessing Exercise Behavior and Preferences Among Patients and Oncologists at Indiana University Simon Cancer Center
IUSCC-0696OPEN TO ACCRUAL
One-on-one exercise program in adolescent and young adult cancer survivors with a certified clinical cancer exercise specialist
IUSCC-0703OPEN TO ACCRUAL
Telephone Support for Advanced Gastrointestinal Cancer Patients and their Family Caregivers
IUSCC-0708OPEN TO ACCRUAL
Genomic Analysis of Relapsed/Refractory Germ-Cell Tumors
IUSCC-0709OPEN TO ACCRUAL
Evaluation of MRM-Profiling as a Small Molecule Biomarker-Enrichment Strategy in Oncological Clinical Trials
J11155OPEN TO ACCRUAL
Pre-Operative PARPi and Irradiation (POPI) in Women with an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast Cancer
J13104OPEN TO ACCRUAL
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0)
KN026-US-I-001OPEN TO ACCRUAL
Phase I Study KN026 in HER2 Expressing Breast Cancer, Gastric/Gastroesophageal Junction Cancer and other Locally Advanced/Metastatic Solid Tumors
LUN17-302OPEN TO ACCRUAL
A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer
LUN17-321OPEN TO ACCRUAL
A Phase II study of Concurrent Chemoradiation plus Durvalumab followed by Surgery followed by Adjuvant Durvalumab in medically operable patients with surgically resectable Stage IIIA (N2) Non-Small Cell Lung Cancer
NEUR-AGIOS-AG881-C-004OPEN TO ACCRUAL
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
NEUR-ECOG-ACRIN-EAF151OPEN TO ACCRUAL
DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
NEUR-SPRINGWORKS-MEK-NF-201OPEN TO ACCRUAL
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity
NRG-GY005OPEN TO ACCRUAL
A RANDOMIZED PHASE II/III SUTDY OF THE COMBINATION OF CEDIRANIB AND OLAPARIB COMPARED TO CEDIRANIB OR OLAPARIB ALONE, OR STANDARD OF CARE CHEMOTHERAPY IN WOMEN WITH RECURRENT PLATINUM-RESISTANT OR REFRACTORY OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (COCOS)
NRG-GY006OPEN TO ACCRUAL
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.
NRG-HN004OPEN TO ACCRUAL
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
NRG-LU003OPEN TO ACCRUAL
A Biomarker-Driven Protocol for Previously Treated ALK-Positive NSCLC Patients: The NCI-NRG ALK Master Protocol
NSRG-IIR-COHEN-DESIOPEN TO ACCRUAL
Evaluation of intraoperative desorption electrospray ionization mass spectrometry for detection of biomolecules indicative of cancerous versus noncancerous disease state in brain tumors using pathology biopsies.
NURS-IIR-CHARRIS-LCSOPEN TO ACCRUAL
Lung Cancer Screening: Identifying Factors Associated with Participantion
OTHN-IIR-IUSCC-0685OPEN TO ACCRUAL
Characterization of Cachexia in Tissues from Head and Neck Surgery Patients Receiving Free Flap Reconstruction.
PHO-BAYER-ADVL1721OPEN TO ACCRUAL
A non-randomized, open-label, multi-center, Phase I/II study of PI3K inhibitor copanlisib in pediatric patients with relapsed/refractory solid tumors or lymphoma
PHO-CIRM-ACESOPEN TO ACCRUAL
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
PHO-COG-AALL1731OPEN TO ACCRUAL
Blinatumomab in Combination With Chemotherapy in Treating Patients With or Without Down Syndrome and Newly Diagnosed, Standard Risk B-Lymphoblastic Leukemia or Localized B-Lymphoblastic Lymphoma.
PHO-COG-AALL1732OPEN TO ACCRUAL
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
PHO-COG-AAML18P1OPEN TO ACCRUAL
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
PHO-COG-ACCL1633OPEN TO ACCRUAL
ACCL1633, The Effectiveness of Lactobacillus plantarum in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
PHO-COG-ACNS1721OPEN TO ACCRUAL
A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
PHO-COG-ACNS1831OPEN TO ACCRUAL
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG).
PHO-COG-ACNS1833OPEN TO ACCRUAL
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
PHO-COG-ADVL1712OPEN TO ACCRUAL
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome.
PHO-COG-ADVL1823OPEN TO ACCRUAL
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia.
PHO-COG-AGCT1532OPEN TO ACCRUAL
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
PHO-COG-AHEP1531OPEN TO ACCRUAL
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
PHO-COG-ANBL1531OPEN TO ACCRUAL
A Phase 3 Study of 131-I-Metaiodobenzylguanidine (131-I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
PHO-COG-ANBL1821OPEN TO ACCRUAL
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
PHO-COG-AREN1721OPEN TO ACCRUAL
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
PHO-COG-CROOP-ADVL1414OPEN TO ACCRUAL
A Phase 1 Study of Selinexor (KPT-330, IND# 125052), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors
PHO-COG-CROOP-ADVL1822OPEN TO ACCRUAL
A PHASE 1/2, MULTI-CENTER, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH RE-INDUCTION CHEMOTHERAPY, AND AS A SINGLE-AGENT MAINTENANCE THERAPY, IN PEDIATRIC RELAPSED/REFRACTORY AML SUBJECTS AGED 1 MONTH TO < 18 YEARS (AND YOUNG ADULTS AGED UP TO 21 YEARS) WITH FLT3-ITD MUTATIONS
PHO-COG-CROOP-AINV18P1OPEN TO ACCRUAL
A PHASE 1 STUDY OF PALBOCICLIB (IND#141416), A CDK 4/6 INHIBITOR, IN COMBINATION WITH CHEMOTHERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) OR LYMPHOBLASTIC LYMPHOMA (LL)
PHO-COG-FALLON-AALL1131OPEN TO ACCRUAL
AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
PHO-COG-FALLON-AAML1531OPEN TO ACCRUAL
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
PHO-COG-FALLON-ADVL1622OPEN TO ACCRUAL
ADVL1622, Phase 2 Trial of XL184 (Cabozantinib), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
PHO-COG-FALLON-AGCT1531OPEN TO ACCRUAL
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
PHO-COG-FALLON-ALTE03N1OPEN TO ACCRUAL
Key Adverse Events Following Childhood Cancer
PHO-COG-FALLON-ALTE07C1OPEN TO ACCRUAL
ALTE07C1, Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
PHO-COG-FALLON-ANBL00B1OPEN TO ACCRUAL
Neuroblastoma Biology Studies
PHO-COG-FALLON-ANBL1232OPEN TO ACCRUAL
ANBL1232, Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
PHO-COG-FALLON-ANHL12P1OPEN TO ACCRUAL
A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)
PHO-COG-FALLON-APEC14B1OPEN TO ACCRUAL
Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
PHO-COG-FALLON-AREN03B2OPEN TO ACCRUAL
Renal Tumors Classification, Biology, and Banking Study
PHO-COG-PEPN1812OPEN TO ACCRUAL
A PHASE 1 TRIAL OF THE CD123 X CD3 DUAL AFFINITY RE-TARGETING ANTIBODY FLOTETUZUMAB (NSC#808294, IND#145986) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
PHO-COG/EISAI-ADVL1711OPEN TO ACCRUAL
A Phase 1/2 Study of Lenvatinib in combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, including CNS tumors
PHO-CROOP-AMGEN-20110261OPEN TO ACCRUAL
A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects with Advanced Non Central Nervous System Tumors That are Amenable to Direct Injection Advanced Non Central Nervous SystemTumors That are Amenable to Direct Injection
PHO-CROOP-COG-ADVL1615OPEN TO ACCRUAL
A PHASE 1 STUDY OF PEVONEDISTAT (MLN4924, IND# 136078), A NEDD8 ACTIVATING ENZYME (NAE) INHIBITOR, IN COMBINATION WITH TEMOZOLOMIDE AND IRINOTECAN IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
PHO-FALLON-COG-AALL1621OPEN TO ACCRUAL
AALL1621, A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
PHO-FALLON-COG-ANHL1522OPEN TO ACCRUAL
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
PHO-FALLON-COG-ARST1431OPEN TO ACCRUAL
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
PHO-FALON-INCYTE-AALL1521OPEN TO ACCRUAL
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant Acute Lymphoblastic Leukemia
PHO-FERG-NOVARTIS-36G2201OPEN TO ACCRUAL
Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive relapsed or refractory High Grade Glioma (HGG)
PHO-IIR-COVID-19-DISTRESSOPEN TO ACCRUAL
Distress during COVID-19 Pandemic for Caregivers of Children with Hematologic and Oncologic Diagnoses.
PHO-IIR-INFECTIOUSDISEASEOPEN TO ACCRUAL
Infectious Disease Outcomes in Pediatric Oncology Patients.
PHO-JANSSEN-AALL2005OPEN TO ACCRUAL
An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects 1 and 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
PHO-LILLY-CROOP-ADVL1416OPEN TO ACCRUAL
A PHASE 1 STUDY OF RAMUCIRUMAB, A HUMAN MONOCLONAL ANTIBODY AGAINST THE VASCULAR ENDOTHELIAL GROWTH FACTOR-2 (VEGFR-2) RECEPTOR IN CHILDREN WITH REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS
PHO-NOVARTIS-CCTL019G2201JOPEN TO ACCRUAL
A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy
PHO-NOVARTISMAPS-SKILESOPEN TO ACCRUAL
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
PHO-PBMTC-ENDRADOPEN TO ACCRUAL
A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative
PHO-PFIZER-PRADHAN-ADVL1921OPEN TO ACCRUAL
PHO-PRADAN-EISAI-ADVL1722OPEN TO ACCRUAL
A Phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS)
PHO-PRADHAN-COG-AALL1631OPEN TO ACCRUAL
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
PHO-PRADHAN-COG-ACNS1422-OPEN TO ACCRUAL
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
PHO-PRADHAN-COG-ADVL1521OPEN TO ACCRUAL
A Phase 2 Study of the MEK Inhibitor Trametinib in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
PHO-PRADHAN-COG-ALTE1631OPEN TO ACCRUAL
A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia
PHO-PRADHAN-COG-ALTE16C1OPEN TO ACCRUAL
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
PHO-PRADHAN-COG-APEC1621OPEN TO ACCRUAL
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)MASTER VERSION CONTROL PROTOCOL
PHO-PRADHAN-MERK-ADVL1621OPEN TO ACCRUAL
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
PHO-SHIH-ASTRA-SELUMETINIOPEN TO ACCRUAL
An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1 with inoperable, progressive/symptomatic plexiform neurofibromas
PHO-SHIH-NWC-HEADSTART4OPEN TO ACCRUAL
NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS: CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WITH EITHER SINGLE CYCLE (LOW RISK PATIENTS) OR RANDOMIZATION (HIGH RISK PATIENTS) TO either SINGLE-CYCLE or TO THREE TANDEM CYCLES OF MARROW-ABLATIVE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE
PHO-STJUDE-AML16OPEN TO ACCRUAL
A PHASE II TRIAL OF EPIGENETIC PRIMING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
PHO-YMABS-201OPEN TO ACCRUAL
A Phase 3 Trial of Antibody hu3F8 and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary or Secondary Refractory Osteomedullary Disease
PHO-YMABS-PRADHAN-101OPEN TO ACCRUAL
A Multicenter Phase 2/ 3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy using 131I-burtomab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
PONATINIB-3001OPEN TO ACCRUAL
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
PSY-IIR-IUSCC-0698OPEN TO ACCRUAL
Telephone Support for Metastatic Breast Cancer Patients
R5459-ONC-1888OPEN TO ACCRUAL
Phase 1/2 FIH Study of REGN5459 (anti-BCMA x anti-CD3 bispecific antibody) in Patients with Relapsed or Refractory Multiple Myeloma
RADY-ECOG-ACRIN-EA8171OPEN TO ACCRUAL
Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer
RADY-ECOG-WESTPHAL-EA1151OPEN TO ACCRUAL
Tomosynthesis Mammographic Imaging Screening Trial (TMIST) EA1151
RADY-FIVEELEVEN-GREEN-GAOPEN TO ACCRUAL
Phase I: Biodistribution and dosimetry of the investigational PET agent 68Ga-P16-093 in prostate cancer patients with biochemical recurrence undergoing clinical 68Ga-PSMA-11 PET/CT Phase II: Biodistribution and dosimetry of the investigational PET agent 68GA-P16-093 in prostate cancer patients.
RADY-GU-SAYKIN-TLCOPEN TO ACCRUAL
Older Breast Cancer Patients: Risk for Cognitive Decline
RADY-IIR-CORRELATIONOPEN TO ACCRUAL
Correlation of Renal Mass Pathologic Grade and CEUS.
RADY-IUSCC-0725OPEN TO ACCRUAL
Yttrium-90 Radiation Segmentectomy versus Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Early Stage Hepatocellular Carcinoma (HCC): A Pilot Study
RAON-CCTG-MA39OPEN TO ACCRUAL
A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER
RAON-ECOG-ACRIN-EA3132OPEN TO ACCRUAL
Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
RAON-IIR-IUSCC-0710OPEN TO ACCRUAL
Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study
RAON-NRG-BN003OPEN TO ACCRUAL
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma.
RAON-NRG-HN005OPEN TO ACCRUAL
A Randomized Phase II/III Trials of De-Intensified Radiation Therapy For patients with Early Stage, P-16, Positive, Non-Smoking Associated Oropharyngeal Cancer.
RAON-NRG-LU005OPEN TO ACCRUAL
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab.
RAON-NRG-RTOG-1008OPEN TO ACCRUAL
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
RAON-STANFORD-AVATAROPEN TO ACCRUAL
AVATAR anesthesia alternative in pediatric radiotherapy: A Multi-Center Pilot Study
RSRB45410OPEN TO ACCRUAL
Genetic Susceptibility and Biomarkers of Platinum-Related Toxicities
S1418/BR006OPEN TO ACCRUAL
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.
S1607OPEN TO ACCRUAL
A PHASE II STUDY OF COMBINING TALIMOGENE LAHERPAREPVEC (T-VEC) (NSC-785349) AND MK-3475 (PEMBROLIZUMAB) (NSC-776864) IN PATIENTS WITH ADVANCED MELANOMA WHO HAVE PROGRESSED ON ANTI-PD1/L1 BASED THERAPY
S1609OPEN TO ACCRUAL
DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS
S1706OPEN TO ACCRUAL
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
S1826OPEN TO ACCRUAL
A PHASE III, RANDOMIZED STUDY OF NIVOLUMAB (OPDIVO) PLUS AVD OR BRENTUXIMAB VEDOTIN (ADCETRIS) PLUS AVD IN PATIENTS (AGE >/= 12 YEARS) WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA NCT# 03907488
SARC024OPEN TO ACCRUAL
SNEU-IIR-RIMTIHOPEN TO ACCRUAL
Role of Inflammatory Mediators in Tumor-Induced Hydrocephalus
STU00077147OPEN TO ACCRUAL
Impact of Genetic Variants on Failure of Active Surveillance for Prostate Cancer
SURG-CLINGEN-ROBB-NOVACLOSED TO ACCRUAL
Evaluation of the Performance of the Clinical Genomics Colvera Test in the Detection of Disease Recurrence in Patients Diagnosed with Colorectal Cancer
SURG-DAVOL-PREVENTOPEN TO ACCRUAL
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial (PREVENT): Prospective, Multi-Center, Open-Label, Randomized, Controlled Trial of Phasix Mesh to Prevent Incisional Hernia Subsequent to Open Midline Laparotomy
SURG-DUKE-CEPPA-VACOPEN TO ACCRUAL
A Randomized Phase II Evaluation of Negative Pressure Wound Therapy for Reduction of Postoperative Surgical Site Infection in Patients Undergoing Colorectal and Hepatopancreatobiliary Surgery
SURG-ETHICON-ROBB-ENSEALCLOSED TO ACCRUAL
A Prospective, Multi-Center Evaluation of the ENSEAL X1 Large Jaw Tissue Sealer
SURG-IIR-COVID-19-RESPONSEOPEN TO ACCRUAL
Impact of the Initial COVID-19 Response and the Following Delayed Care Surge on Patients Requiring Emergent, Urgent, and Elective Surgical Procedures
SURG-IIR-CTDNAOPEN TO ACCRUAL
A phase I feasibility study to identify circulating tumor DNA in patients with Barrett's epithelium and early stage esophageal adenocarcinoma treated with endoscopic mucosal resection
SURG-MSK-HOUSE-ANTIBIOTICOPEN TO ACCRUAL
A Phase III Multicenter, Open Label Randomized Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy
SURG-TAKEDA-954-2004OPEN TO ACCRUAL
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperative Gastrointestinal Dysfunction in Patients Undergoing Large- and Small-Bowel Resection
TBCRC034OPEN TO ACCRUAL
The incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in patients diagnosed with Flat Epithelial Atypia (FEA) or Intraductal Papilloma without Atypia (IPWA) by Core Needle Biopsy
TBCRC038OPEN TO ACCRUAL
DIVERSITY IN THE TUMOR GENOME AND MICROENVIRONMENT AS DRIVERS OF DCIS PROGRESSION
TBCRC043OPEN TO ACCRUAL
A Phase II trial of Atezolizumab (anti-PDL1) with Carboplatin in Patients with Metastatic Triple Negative Breast Cancer
TBCRC044OPEN TO ACCRUAL
A Randomized Phase II Study of Pembrolizumab, an anti-PD (programmed cell death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease
TBCRC045OPEN TO ACCRUAL
A RANDOMIZED, PHASE II STUDY COMPARING TRASTUZUMAB AND VINORELBINE IN COMBINATION WITH AVELUMAB OR AVELUMAB AND UTOMILUMAB (41BB/CD137 AGONIST), IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER WHO HAVE PROGRESSED ON PRIOR TRASTUZUMAB AND PERTUZUMAB: The "AVIATOR Study
TBCRCADM-002OPEN TO ACCRUAL
Translational Breast Cancer Research Consortium Biospecimen & Outcomes Repository
VB-111-701/GOG-3018OPEN TO ACCRUAL
The OVAL Study: A Randomized, Controlled, Double-Arm,Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
VEDOLIZUMAB-3035OPEN TO ACCRUAL
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation